Novel fat accumulation inhibitory peptide and pharmaceutical composition for preventing or treating obesity containing the same

Abstract

The present invention relates to a fat accumulation inhibitory peptide which essentially comprises an amino acid sequence represented by SEQ ID NO: 1, a pharmaceutical composition for preventing or treating obesity, which contains the peptide, and a health functional food for preventing or alleviating obesity, which contains the peptide. The fat accumulation inhibitory peptide according to the present invention has the function of inhibiting the differentiation of mesenchymal stem cells into adipocytes to thereby inhibit the accumulation of adipose tissue. Thus, the peptide according to the present invention is highly useful for the prevention or treatment of obesity.

1 . A fat accumulation inhibitory peptide which essentially comprises an amino acid sequence represented by SEQ ID NO: 1. 
     
     
         2 . The fat accumulation inhibitory peptide of  claim 1 , wherein the fat accumulation inhibitory peptide consists of an amino acid sequence represented by SEQ ID NO: 2. 
     
     
         3 . The fat accumulation inhibitory peptide of  claim 1 , wherein the peptide acts to inhibit the differentiation of mesenchymal stem cells into adipocytes. 
     
     
         4 . A pharmaceutical composition for preventing or treating obesity, which contains the fat accumulation inhibitory peptide of  claim 1 . 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the obesity is obesity caused estrogen deficiency. 
     
     
         6 . The pharmaceutical composition of  claim 4 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. 
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the pharmaceutically acceptable carrier is at least one selected from the group consisting of physiological saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, and ethanol. 
     
     
         8 . The pharmaceutical composition of  claim 4 , wherein the pharmaceutical composition further contains at least one additive selected from the group consisting of an excipient, a buffer, an antimicrobial preservative, a surfactant, an antioxidant, a tonicity adjuster, a preservative, a thickener, and a viscosity modifier. 
     
     
         9 . The pharmaceutical composition of  claim 4 , wherein the pharmaceutical composition is formulated for oral administration, injection administration or in the form of a gelling agent for local transplantation. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the gelling agent for local transplantation comprises a synthetic polymer or a natural polymer. 
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein the synthetic polymer is any one selected from the group consisting of polylacticglycolic acid, poloxamer, and propylene glycol. 
     
     
         12 . The pharmaceutical composition of  claim 10 , wherein the natural polymer is any one selected from the group consisting of collagen, alginic acid, propylene glycol alginic acid, chondroitin sulfate, and chitosan. 
     
     
         13 . The pharmaceutical composition of  claim 4 , wherein the fat accumulation inhibitory peptide is administered in an amount of 1-60 mg per kg of body weight of a subject to be treated. 
     
     
         14 . A health functional food for preventing or alleviating obesity, which contains the fat accumulation inhibitory peptide of  claim 1 . 
     
     
         15 . The health functional food of  claim 14 , wherein the obesity is caused by estrogen deficiency.